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Aviv, Israel; 3Medical Division, Maccabi Healthcare Services, Tel Aviv, IsraelA B S T R A C TBackground: The 2013 American College of Cardiology and American
Heart Association (ACC/AHA) guidelines for the management of blood
cholesterol identify candidates for statin therapy to prevent athero-
sclerotic cardiovascular disease (ASCVD). Objective: The objective was
to estimate the effect of adopting the ACC/AHA guidelines in Maccabi
Healthcare Services (MHS), a large health maintenance organization in
Israel.Methods: This population-based study, conducted in June 2014,
included all MHS members 40 years or older. We searched the
computerized database of MHS to determine the number of members
currently on statins, calculated the number of additional members
newly eligible for statin treatment according to the new guidelines,
and estimated the cost of implementing the guidelines in MHS.
Results: In June 2014, there were 798,076 MHS members 40 years or
older. Of the 725,784 members included, 30% were receiving statin
treatment at baseline. Adopting the new guidelines would increase theee front matter Copyright & 2015, International S
r Inc.
.1016/j.vhri.2015.05.001
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ndence to: Amir Nutman, Division of Epidemiologyproportion of statin-treated members to 48% (58% and 39% among
men and women, respectively). Newly eligible members were more
likely to be 55 to 69 years old, men, and have a predicted 10-year
ASCVD risk of 7.5% or more. The calculated incremental annual cost
for medications is 54 million new Israeli shekels (US $13.5 million). The
cost per cardiovascular event prevented is estimated at 82,000 new
Israeli shekels (US $20,500). Conclusions: Adopting the ACC/AHA 2013
cholesterol guidelines would increase the number of MHS members 40
years or older eligible for statin therapy by 60%, with the increase
mainly in primary prevention due to the predicted 10-year ASCVD risk.
Keywords: cholesterol guidelines, application, cost, eligibility, statin
therapy, population-based.
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Cardiovascular disease is the second leading cause of death in
Israel [1]. Lifestyle and risk factor modiﬁcation and pharmaco-
logical interventions are essential in reducing cardiovascular
events. Statins play a key role in both primary and secondary
prevention [2,3]. The American College of Cardiology and the
American Heart Association (ACC/AHA) published new guidelines
for the management of blood cholesterol in November 2013 [4]
replacing the National Cholesterol Education Program Adult
Treatment Panel III (ATP III) guidelines published over a decade
ago [5].
The ACC/AHA 2013 guidelines abandon the previous paradigm
of treating according to speciﬁc low-density lipoprotein choles-
terol (LDL-C) targets. Instead, the new guidelines recommend
statin therapy for patient groups for whom statins reduced the
risk of atherosclerotic cardiovascular disease (ASCVD), including
coronary heart disease and stroke, in randomized controlled
trials. The ACC/AHA 2013 guidelines identify four patient groupswho are candidates for statin therapy: 1) patients with clinical
ASCVD (acute coronary syndrome, myocardial infarction, stable
angina, coronary or other arterial revascularization, stroke, tran-
sient ischemic attack, and peripheral arterial disease of athero-
sclerotic origin); 2) patients with LDL-C levels of 190 mg/dl or
more; 3) 40- to 75-year-old patients with diabetes and LDL-C
levels of 70 to 189 mg/dl; and 4) 40- to 75-year-old patients
without diabetes, with LDL-C levels of 70 to 189 mg/dl and a
predicted 10-year ASCVD risk of 7.5% or more, as calculated by
the new pooled cohort equations published along with the
guidelines [6].
Following the publication of the new guidelines, concern
arose that they would substantially expand the population
eligible for statin treatment [7–10]. Pencina et al. [11] estimated
that the number of US adults receiving or eligible for statin
therapy would increase from 43 million (37.5% of US adults) to
56 million (48.6%). Among 60- to 75- year-old adults not receiving
statin therapy, 87.4% of men and 53.6% of women would be
eligible for treatment [11].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Services (MHS), the second largest national health maintenance
organization in Israel, in the context of updating statin treatment
policy; MHS is considering adopting the ACC/AHA 2013 guide-
lines. Our aims were to determine the number of members 40
years or older currently on statins, to estimate the number who
would be eligible for statins under the new guidelines, and to
estimate the cost of treating these additional patients.Methods
Study Population
The study population included all MHS members 40 years and
older on June 2014. Members were stratiﬁed into the primary
prevention group (i.e., no history of ASCVD events) or the
secondary prevention group (i.e., history of ASCVD events).
Members whose blood cholesterol levels were never tested were
excluded from the study. In the primary prevention group,
members with LDL-C levels of less than 190 mg/dl, with no
indication of diabetes, who never purchased statins were
excluded if data were not available on blood pressure measure-
ment and smoking history because these variables are required
for ASCVD risk calculation.Table 1 – Demographic and medical characteristics
of study sample.
Characteristic History of
ASCVD* (eligible
for statins for
secondary
prevention)
(N ¼ 72,266)
No history of
ASCVD (possibly
eligible for statins
for primary
prevention)
(N ¼ 653,518)
Age (y), mean  SD 69  11.8 55.8  11.7
Sex: male, n (%) 50,816 (70.3) 289,832 (44.3)
Diabetes mellitus,
n (%)
27,195 (37.6) 79,234 (12.1)
Hypertension,
n (%)
49,749 (68.8) 196,589 (30.1)
Smoking current,
n/total N (%)
11,888/70,593 (16.8) 103,377/646,359
(16.0)
Currently on
statins, n (%)
56,922 (78.8) 163,838 (25.1)
* Atherosclerotic cardiovascular disease (ASCVD) includes
ischemic heart disease, stroke, transient ischemic attack, and
peripheral artery disease.Study Variables and Deﬁnitions
Data for this study were obtained from MHS’s computerized
databases. For each member, data collected included age; sex;
smoking status; last systolic blood pressure measurement; his-
tory of clinical ASCVD (i.e., ischemic heart disease, stroke,
transient ischemic attack, or peripheral artery disease) as docu-
mented in the MHS cardiovascular registry [12]; history of
diabetes as documented in the MHS diabetes registry [13]; history
of hypertension as documented in the MHS hypertension registry
[14]; and results of the most recent blood tests for total choles-
terol, LDL-C, and high-density lipoprotein cholesterol, HDL-C. We
also collected data from the pharmacy database on antihyper-
tensive medications and statin medications that had been dis-
pensed during the previous 6 months. The most recently
dispensed statin was characterized by drug (simvastatin, ator-
vastatin, rosuvastatin, pravastatin, or ﬂuvastatin) and dose.
Intensity of statin therapy was graded according to the ACC/
AHA 2013 guidelines [4]. Members for whom no statins had been
dispensed during the previous 6 months were deﬁned as not
receiving statin treatment.
Members receiving statins were categorized as being treated
for primary or secondary prevention. Among members not
currently receiving statins, those who would become eligible for
statins under the new guidelines were identiﬁed according to the
ACC/AHA 2013 criteria: 1) clinical ASCVD; 2) LDL-C levels of
190 mg/dl or more; 3) LDL-C levels of 70 to 189 mg/dl in persons
aged 40 to 75 years with diabetes; and 4) LDL-C levels of 70 to
189 mg/dl and a 10-year ASCVD risk of 7.5% or more, as calculated
by the pooled cohort equations [6], in persons aged 40 to 75 years
without diabetes. The variables used to calculate the 10-year
ASCVD risk were age, sex, race, systolic blood pressure, total
cholesterol, HDL-C, smoking status, use of antihypertensive
medications, and history of diabetes [6].
To assess the cost of statin therapy for members eligible for
treatment under the new guidelines, we consulted the Israeli
Ministry of Health’s price list for prescription medications [15].
For moderate-intensity treatment, we used the retail price of
generic simvastatin 20 mg, 20.4 new Israeli shekels (NIS) per
month per patient (US $5.1); for high-intensity treatment, weused the retail price of generic atorvastatin 40 mg, 62.1 NIS per
month per patient (US $15.5).
Statistical Analysis
Data were summarized descriptively. Continuous variables were
reported as mean  SD, or as median with interquartile range if
not normally distributed, and discrete values were reported as
proportions. Demographic and medical characteristics were com-
pared between members currently on statins and those newly
eligible for statins. Statistical analysis was performed using IBM
SPSS Statistics, version 21 (IBM Corporation, Armonk, NY).
The study was approved by the institutional review board of
Assuta Medical Center, Tel Aviv, which oversees research con-
ducted at MHS.Results
In June 2014, there were 798,076 registered MHSmembers 40 years
or older. The data required for inclusion in our analysis were
available for 725,784 members (91%). Of these, 72,266 members
had a history of ASCVD events (mean age 69  12 years, 70% men)
and 653,518 members had no previous ASCVD events (mean age
56  12 years, 44% men). Seventy-nine percent of the members
with a history of ASCVD events and 25% of the members with no
previous ASCVD events were currently on statins (Table 1). The
most frequently dispensed regimen (for either primary or secon-
dary prevention) was simvastatin 10 mg for low-intensity treat-
ment, simvastatin 20 mg for moderate-intensity treatment, and
atorvastatin 40 mg for high-intensity treatment.
If the ACC/AHA 2013 guidelines were fully implemented in
MHS members 40 years or older included in our study, 127,010
additional members (17.5%) would be eligible for statin treatment
(Table 2). Of these, 15,344 would be eligible for statins for
secondary prevention and 111,666 for primary prevention. Com-
parison of the characteristics of members currently on statins
and newly eligible members for secondary prevention is sum-
marized in Table 3, and for primary prevention is summarized in
Table 4. Fig. 1 illustrates the distribution of indications for statin
treatment eligibility for primary prevention, by sex and age,
under the new guidelines. Most of the newly eligible persons
Table 2 – Comparison of statin treatment and eligibility by sex and age group.
Sex Age group (y) N Currently on statins, n (%) Additional members newly
eligible for statins, n (%)
Female 40–54 190,518 15,340 (8.1) 7,274 (3.8)
55–69 130,473 53,836 (41.3) 23,483 (18.0)
Z70 64,145 37,495 (58.5) 11,621 (18.1)
All age groups 385,136 106,671 (27.7) 42,378 (11.0)
Male 40–54 172,493 29,029 (16.8) 23,253 (13.5)
55–69 117,604 54,004 (45.9) 51,333 (43.6)
Z70 50,551 31,056 (61.4) 10,046 (19.9)
All age groups 340,648 114,089 (33.5) 84,632 (24.8)
Both 40–54 363,011 44,369 (12.2) 30,527 (8.4)
55–69 248,077 107,840 (43.5) 74,816 (30.2)
Z70 114,696 68,551 (59.8) 21,667 (18.9)
All age groups 725,784 220,760 (30.4) 127,010 (17.5)
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is a predicted 10-year ASCVD risk of 7.5% or more.
Among MHS members treated with statins, many were not
receiving a statin with appropriate intensity as recommended
by the ACC/AHA 2013 guidelines [4]. In our sample, only 46% of
the members 75 years or younger on statins for secondary
prevention were receiving a high-intensity regimen as indicated
by the guidelines. Moreover, 8% of the members on statins for
secondary prevention and 17% of the members on statins for
primary prevention were receiving low-intensity regimens,
which are not recommended by the recent guidelines (Table 5).
Adopting the new guidelines would therefore necessitate esca-
lating statin treatment for more than 51,000 members. Further-
more, the guidelines recommend a moderate-intensity regimen
for secondary prevention in patients older than 75 years. In our
sample, 4935 members older than 75 years on statins for
secondary prevention were receiving a high-intensity regimen.Table 3 – Comparison of members newly eligible for
statin treatment for secondary prevention and
those currently treated for secondary prevention.
Characteristic Newly eligible
for statins (N ¼
15,344)
Currently on
statins (N ¼
56,922)
Age (y), mean  SD 69.0  14.3 69.0  11.0
Sex: male, n (%) 9,403 (61.3) 41,413 (72.8)
Diabetes mellitus,
n (%)
3,850 (25.1) 23,345 (41.0)
Hypertension, n (%) 9,514 (62.0) 40,235 (70.7)
Systolic blood
pressure (mm
Hg), mean  SD
130.0  17.6 130.4  16.1
Smoking
Current, n/total
N (%)
2,534/14,805
(17.1)
9,354/55,788
(16.8)
Past, n/total N (%) 708/14,805 (4.8) 3,499/55,788 (6.3)
Cholesterol
LDL (mg/dl), mean
 SD
115.3  35.3 88.3  30.6
HDL (mg/dl),
mean  SD
48.0  13.0 45.5  11.9
TC (mg/dl), mean
 SD
191.0  43.1 162.0  38.1
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC,
total cholesterol.The guidelines do not generally recommend statin treatment for
primary prevention in patients older than 75 years unless LDL-C
levels are 190 mg/dl or more. In our sample, 26,545 members
receiving statins for primary prevention were older than 75
years, potentially needing re-evaluation of treatment indication
(Table 5).
We examined results of LDL-C tests in members newly eligible
for statins to determine what proportion of them had LDL-C
levels below the cutoff at which treatment is recommended in
the ATP III guidelines. In members with ASCVD newly eligible for
statin treatment for secondary prevention, the mean LDL-C level
was 115  35 mg/dl and 35% had an LDL-C level of less than
100 mg/dl, the LDL-C target for secondary prevention recom-
mended by the ATP III guidelines [5]. In members with diabetes
newly eligible for statin treatment for primary prevention, theTable 4 – Comparison of members newly eligible for
statin treatment for primary prevention and those
currently treated for primary prevention.
Characteristic Newly eligible
for statins (N ¼
111,666)
Currently on
statins (N ¼
163,838)
Age (y), mean  SD 60.7  8.4 63.4  10.9
Sex: males, n (%) 75,229 (67.4) 72,676 (44.4)
Diabetes mellitus,
n (%)
19,771 (17.7) 53,953 (32.9)
Hypertension, n (%) 45,769 (41.0) 94,732 (57.8)
Systolic blood
pressure (mm
Hg), mean  SD
131.4  15.7 129.1  15.2
Smoking
Current, n/ total
N (%)
33,380 (30.2) 24,381 (15.3)
Past, n/total N (%) 3,273 (3.0) 5,326 (3.3)
Cholesterol
LDL (mg/dl),
mean  SD
134.2  34.0 110.2  36.3
HDL (mg/dl),
mean  SD
48.5  12.7 51.3  13.0
TC (mg/dl), mean
 SD
211.9  40.1 190.5  42.7
10-y risk score (p),
median (IQR)
0.12 (0.09– 0.17) NA
HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-
density lipoprotein; NA, not applicable; TC, total cholesterol.
Fig. 1 – Newly eligible members for statin treatment by sex, age group, and ACC/AHA 2013 criteria for primary prevention.
ACC, American College of Cardiology; AHA, American Heart Association.
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of less than 100 mg/dl, the LDL-C target for primary prevention in
persons with diabetes recommended by the ATP III guidelines [5].
In nondiabetic members newly eligible for statin treatment for
primary prevention, the mean LDL-C level was 138  34 mg/dl
and 46% had an LDL-C level of less than 130 mg/dl, the LDL-C
target for primary prevention recommended by the ATP III
guidelines for patients in the intermediate-risk category (multiple
risk factors and 10-year risk r 20%) [5].
The annual incremental cost of fully implementing the ACC/
AHA 2013 guidelines in MHS members was estimated at 11.4
million NIS (US $2.8 million) for untreated persons eligible for
statin therapy for secondary prevention and 32 million NIS (US $8
million) for untreated persons eligible for statin therapy for
primary prevention (7 million NIS [US $1.7 million] for untreated
persons with an LDL level of Z190 mg/dl, 4.7 million NIS [US $1.2
million] for untreated persons with diabetes mellitus, and
20.3 million NIS [US $5 million] for untreated persons with a
predicted risk score of Z7.5%). The additional cost of escalating
current users’ statin therapy to the appropriate intensity as
recommended by the new guidelines was estimated at 10.5
million NIS (US $2.6 million) per year. Thus, the expected totalTable 5 – Distribution of dispensed statins by intensity,
Intensity Currently on statins for secondary prevention
(N ¼ 56,922), n (%)
Age r 75 y (N ¼ 38,593) Age 4 75 y (N ¼ 18,32
Low 2,131 (5.5) 2,340 (12.8)
Moderate 18,559 (48.1) 11,054 (60.3)
High 17,903 (46.4) 4,935 (26.9)annual incremental cost of medications for fully implementing
the ACC/AHA 2013 guidelines in MHS members was estimated at
54 million NIS (US $13.5 million).
Assuming the validity of the 10-year risk score in the Israeli
population, there would be an estimated 15,600 new cases of
ASCVD events over the next 10 years among the 111,666 MHS
members eligible for primary prevention who are not currently
receiving statin therapy (mean ASCVD risk score of 0.14). The likely
effect of fully implementing the guidelines on future ASCVD
events in this group, assuming that statin therapy reduces the
relative cardiovascular risk by 25% in primary prevention [3],
would be approximately 3900 future events prevented. The cost
per event prevented is estimated at 82,000 NIS (US $20,500).Discussion
Over the past decade, statin use has steadily increased in Israel
and there has been a shift toward statin initiation in lower risk
populations, speciﬁcally, younger patients with lower LDL-C
levels and without a history of ASCVD [16]. The introduction of
the ACC/AHA 2013 guidelines on cardiovascular risk assessmentindication, and age group.
Currently on statins for primary prevention
(N ¼ 163,838), n (%)
9) Age r 75 y (N ¼ 137,293) Age 4 75 y (N ¼ 26,545)
22,362 (16.3) 5,906 (22.2)
92,147 (67.1) 17,546 (66.1)
22,784 (16.6) 3,093 (11.7)
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prevention based on a 10-year ASCVD risk of 7.5% or more, thus
potentially expanding the population eligible for treatment [6].
We sought to gain insight into the characteristics and number of
newly eligible members for statin treatment and estimate the
cost of implementing the new guidelines. Our study is unique in
including all registered MHS members older than 40 years, and
not a selected cohort, for providing a reliable forecast.
The results of this study indicate that adopting the ACC/AHA
2013 guidelines would increase the population eligible for statin
therapy by an additional 17.5%, mainly for primary prevention
based on a predicted 10-year ASCVD risk of 7.5% or more.
Assuming that members currently on statins would remain
treated, the proportion of MHS members older than 40 years
requiring statin therapy would increase to 47.9% (58.3% of men
and 38.7% of women): 73.6% of persons 55 to 69 years old (89.6%
of men and 59.3% of women) and 78.7% of persons 70 years or
older (81.3% of men and 76.6% of women). Pencina et al. [11]
reported similar results in the US population.
The cost of adopting the new guidelines is estimated at 54
million NIS (US $13.5 million) annually, of which 32 million NIS
(US $8 million) is for primary prevention in newly eligible MHS
members. The likely effect of fully implementing the guidelines
on future ASCVD events in this group, assuming the validity of
the 10-year risk score in the Israeli population, and that statin
therapy reduces the relative cardiovascular risk by 25% in
primary prevention [3], would be approximately 3900 events
prevented in 10 years. The cost per event prevented is estimated
at 82,000 NIS (US $20,500).
Our study has some potential limitations. First, data were
obtained from computerized patient records and automated
patient registries, thus relying on the accuracy and completeness
of these records. We excluded 72,292 members (9% of MHS
members 40 years or older): 47,116 members without available
blood cholesterol test results and 25,176 members without
available smoking history. This group, however, is younger (mean
age 51 years) and generally healthy; the prevalence of ASCVD was
0.5%, and the prevalence of diabetes was 0.8%, and only 1364
(1.9%) received statin therapy. Thus, this exclusion did not alter
study results signiﬁcantly. A second limitation is that data on
statin treatment were obtained from pharmacy records of dis-
pensed drugs. We did not compare these data with physician
orders; some patients eligible for statin therapy may have been
prescribed treatment but did not acquire the medication. Third,
because this is a cross-sectional survey, we could not evaluate
the appropriateness of statin treatment according to the ACC/
AHA 2013 guidelines in members already receiving such therapy.
A previous study estimated that 0.8% to 1.8% of the patients
eligible for statins under the ATP III guidelines would no longer
be eligible under the new guidelines [11]. Accurate calculation of
10-year ASCVD risk requires the results of cholesterol tests in the
absence of statin treatment, which is not possible in patients
currently on statins. Therefore, it is most likely in clinical practice
that MHS members who began statins under the old guidelines
will continue them under the new guidelines. Fourth, we did not
include members younger than 40 years, because the ACC/AHA
2013 guidelines for risk assessment do not have speciﬁc guide-
lines for primary prevention in this group [6]. Fifth, a prospective
trial is necessary to validate the pooled cohort equations in the
Israeli population [17,18]. Sixth, our cost calculations were
based on the current price of statins in Israel. If prices were to
decline, the cost-effectiveness of expanding statin therapy would
increase. Furthermore, we did not include other direct costs of
treatment, such as physician visits and care for adverse effects.
In conclusion, the implementation of the AHA/ACC 2013
cholesterol guidelines in MHS would increase the number of MHSmembers 40 years or older eligible for statin therapy by 60%, with
the increase indicated mainly for primary prevention based on a
predicted 10-year ASCVD risk of 7.5% or more. The cost of adopting
the new guidelines is estimated at 54 million NIS (US $13.5 million)
annually. Lowering blood cholesterol in the population at risk,
however, would prevent ASCVD events, thus potentially mitigating
the potential adverse effects from this therapy and added costs.Acknowledgment
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